论文部分内容阅读
目的观察莫沙必利联合帕罗西汀治疗功能性消化不良的临床疗效。方法将112例功能性消化不良患者随机分为治疗组和对照组(各56例)。两组均给予莫沙必利5 mg,每日3次口服;治疗组在此基础上加用帕罗西汀20 mg/d,晨服,疗程均为4周。结果治疗组的显效率(67.9%)和总有效率(89.3%)均优于对照组(分别为41.1%和69.6%,P<0.01和P<0.05)。治疗组治疗后的HAMA和HAMD评分均显著低于对照组(P均<0.01)。治疗组在治疗后3月的复发率(12.5%)也明显低于对照组(30.4%,P<0.05)。结论莫沙必利联合帕罗西汀治疗功能性消化不良疗效好,不良反应少。
Objective To observe the clinical efficacy of mosapride and paroxetine in the treatment of functional dyspepsia. Methods One hundred and twelve patients with functional dyspepsia were randomly divided into treatment group and control group (56 cases each). Both groups were given mosapride 5 mg orally 3 times a day; the treatment group was treated with paroxetine 20 mg / d on the basis of morning service, and the course of treatment was 4 weeks. Results The effective rate (67.9%) and total effective rate (89.3%) in the treatment group were better than those in the control group (41.1% and 69.6%, P <0.01 and P <0.05, respectively). The scores of HAMA and HAMD in the treatment group were significantly lower than those in the control group (all P <0.01). The recurrence rate (12.5%) of the treatment group after 3 months of treatment was also significantly lower than that of the control group (30.4%, P <0.05). Conclusion Mosapride combined with paroxetine has good curative effect on functional dyspepsia and few adverse reactions.